RecruitingPhase 1Phase 2NCT07396584

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumors

Sponsor

Hutchmed

Enrollment

186 participants

Start Date

Mar 4, 2026

Study Type

INTERVENTIONAL

Conditions

Solid Tumors, Adult

Summary

This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HMPL-A580 and a drug called HMPL-A580 for people with solid tumors, adult. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHMPL-A580

Part A(Phase I) Dose Escalation Enrolled participants will receive HMPL-A580 treatment in a dose escalation setting initially at 6 predefined dose levels.

DRUGHMPL-A580

Part B(Phase IIa) Dose Expansion/Dose Optimization Evaluate the safety and preliminary anti-tumor activity of HMPL-A580 in selected solid tumors.

Locations(14)

University of California Irvine Medical Center

Orange, California, United States

BRCR Global

Plantation, Florida, United States

Florida Clinical Trials Group LLC (Plantation)

Plantation, Florida, United States

Florida Clinical Trials Group LLC (Tamarac)

Tamarac, Florida, United States

Emory Winship Cancer Institute

Atlanta, Georgia, United States

University of Washington/Fred Hutchinson Cancer Center

Seattle, Washington, United States

Jilin Provincial Cancer Hospital

Changchun, China

Hunan Cancer Hospital

Changsha, China

Shandong Cancer Hospital

Jinan, China

Guangxi Medical University Cancer Hospital

Nanning, China

Shanghai East Hospital

Shanghai, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China

The First Affiliated Hospital of Xiamen University

Xiamen, China

Henan Cancer Hospital

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07396584

Related Trials

GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors

NCT054303735 locations

A Study of GC203 TIL in Advanced Solid Tumors (NF)

NCT07256756

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

NCT0722824715 locations

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT0576813965 locations

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT058618952 locations